SymBiosis Capital Partners, LLC — 13F Holdings & Portfolio
CIK 2006045 · latest 13F-HR filed 2026-05-12
SymBiosis Capital Partners, LLC manages $52.8M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are EVMN (55.80%), IVA (24.76%), WVE (10.30%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position and exited 6; 2 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-05-12
vs 2025-12-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q1 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q4 25 → Q1 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
2 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 100%Cumulative share of the portfolio held in the largest N positions.
SUITE 510
BENTONVILLE, AR 72712
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| 801 INVESTMENTS, LLC Control | INVESTOR MEMBER | 75% or more | Domestic Entity |
| UGWUMBA, CHIDOZIE, KERMICHAEL Control | MANAGING PARTNER | Less than 5% | Individual |
| WALTON, STEUART L Control | MANAGER, BENEFICIARY | 75% or more | Individual |
| WALTON, THOMAS L Control | MANAGER, BENEFICIARY | 75% or more | Individual |
| BROWN, ISAIAH, SCOTT | CHIEF COMPLIANCE OFFICER | Less than 5% | Individual |
| SLW PORTFOLIO, LLC | INVESTOR MEMBER | 10–25% | Domestic Entity |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Trims
- Rani Therapeutics Holdings, Inc.-$5.8M -68.3%
- Clene Nanomedicine Inc.-$2.4M -53.0%
- Surrozen, Inc.-$600 -20.0%
Exited Positions
- Verastem Inc$15.4M
- Aldeyra Therapeutics Inc$13.2M
- Precigen Inc$12.5M
- Nuvation Bio Inc$11.2M
- Aardvark Therapeutics, Inc.$6.3M
SymBiosis Capital Partners, LLC Holdings (2026-03-31)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Evommune, Inc. | EVMN | 30054Y107 | $29.4M | 55.80% | 1,280,778 | SH |
| 2 | Inventiva S.A. | IVA | 46124U107 | $13.1M | 24.76% | 2,354,000 | SH |
| 3 | Wave Life Sciences Ltd. | WVE | Y95308105 | $5.4M | 10.30% | 750,000 | SH |
| 4 | Rani Therapeutics Holdings, Inc. | RANI | 753018100 | $2.7M | 5.11% | 3,667,585 | SH |
| 5 | Clene Nanomedicine Inc. | CLNN | 185634201 | $2.1M | 4.03% | 431,094 | SH |
| 6 | Surrozen, Inc. | SRZN | 86889P117 | $2.4K | 0.00% | 150,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | $52.8M | 6 | 0002006045-26-000007 |
| 2025-12-31 | 2026-02-12 | $109.5M | 11 | 0002006045-26-000002 |